DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Phase 2

Recruiting

Conditions: Type 2 Diabetes (T2D)

Interventions: Drug: NNC0487-0111 subcutanous
Drug: Placebo (NNC0487-0111 subcutanous)
Drug: NNC0487-0111 oral
Drug: Placebo (NNC0487-0111 oral)

First Posted Date: 2024-08-07

Last Posted Date: 2025-04-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 432

Registration Number: NCT06542874

Locations: 🇬🇷
"Laiko" General Hospital of Athens, Goudi/Athens, Greece
🇭🇺
Debreceni Egyetem, Debrecen, Hungary
🇭🇺
Békés Megyei Központi Kórház, Gyula, Hungary

and more 91 locations

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Monlunabant
Drug: Placebo (monlunabant)

First Posted Date: 2024-08-07

Last Posted Date: 2024-12-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 73

Registration Number: NCT06542536

Locations: 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Phase 3

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Tirzepatide
Drug: Cagrilintide
Drug: Semaglutide

First Posted Date: 2024-08-02

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1023

Registration Number: NCT06534411

Locations: 🇺🇸
South Broward Research LLC, Miramar, Florida, United States
🇺🇸
West Orange Endocrinology, Ocoee, Florida, United States
🇺🇸
Optimal Research Sites, Orange City, Florida, United States

and more 141 locations

Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes

Completed

Conditions: Type 2 Diabetes

Interventions: Other: No treatment given

First Posted Date: 2024-07-24

Last Posted Date: 2024-08-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 752

Registration Number: NCT06517784

Locations: 🇮🇳
Novo Nordisk India, Bangalore, India

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

Phase 1

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0519-0130
Drug: Levonorgestrel + Ethinylestradiol
Drug: Paracetamol

First Posted Date: 2024-07-22

Last Posted Date: 2025-03-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 37

Registration Number: NCT06513104

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 209

Registration Number: NCT06507475

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2024-06-27

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 304

Registration Number: NCT06478550

Locations: 🇬🇷
University Hospital of Athens ATTIKON, Athens, Attica, Greece
🇬🇷
General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Nea Efkarpia, Greece
🇬🇷
"Laiko" General Hospital of Athens, Goudi/Athens, Greece

and more 3 locations

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: NNC0487-0111 (formulation D)
Drug: NNC0487-0111 (formulation C)

First Posted Date: 2024-06-27

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 120

Registration Number: NCT06478563

Locations: 🇺🇸
Celerion, Lincoln, Lincoln, Nebraska, United States

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: NNC0487-0111 A
Drug: NNC0487-0111 C
Drug: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
Drug: Acetaminophen - 500 mg/15 ml

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT06461039

Locations: 🇨🇦
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia

Interventions: Drug: Etavopivat

First Posted Date: 2024-05-30

Last Posted Date: 2024-10-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 16

Registration Number: NCT06433661

Locations: 🇺🇸
ICON-Salt Lake City, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy